Medico Remedies

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE630Y01024
  • NSEID: MEDICO
  • BSEID: 540937
INR
53.26
-0.14 (-0.26%)
BSENSE

Dec 05

BSE+NSE Vol: 80.55 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
{
  "main_header": {
    "sid": 1002925,
    "name": "Medico Remedies",
    "stock_name": "Medico Remedies",
    "full_name": "Medico Remedies Ltd",
    "name_url": "stocks-analysis/medico-remedies",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "53.26",
    "chg": -0.14,
    "chgp": "-0.26%",
    "dir": -1,
    "prev_price": "53.40",
    "mcapval": "441.97 Cr",
    "mcap": "Micro Cap",
    "scripcode": 540937,
    "symbol": "MEDICO",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE630Y01024",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "80.55 k",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/medico-remedies-1002925-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Medico Remedies Sees Shift in Market Assessment Amid Strong Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/medico-remedies-upgraded-to-buy-by-marketsmojo-on-strong-technical-and-financial-grounds-3747930",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/MedicoRemedies_mojoScore_3747930.png",
        "date": "2025-12-05 08:14:51",
        "description": "Medico Remedies, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable revision in its market evaluation, reflecting a combination of robust financial results and evolving technical indicators. This shift highlights the company's recent performance across quality, valuation, financial trends, and technical parameters, offering investors a comprehensive view of its current standing."
      },
      {
        "title": "How has been the historical performance of Medico Remedies?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-medico-remedies-3747127",
        "imagepath": "",
        "date": "2025-12-04 22:51:46",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue Growth and Operating Performance</strong></p>\n<p>Over the past seven years, Medico Remedies has seen its net sales rise from ₹97.69 crores in March 2019 to ₹150.94 crores in March 2025, reflecting a robust compound growth trend. The company’s total operating income mirrors this progression, with no other operating income reported, indicating a primary reliance on core business activities. Raw material costs have naturally increased in line with sales, reaching ₹111.39 crores in the latest fiscal year, while employee costs have also risen steadily, signalling investment in human capital to support expansion.</p>\n<p>Operating profit before depreciation and interest (PBDIT) excluding other income has improved significantly, from ₹2.76 crores in 2019 to ₹15.00 crores in 2025. When factor..."
      },
      {
        "title": "Medico Remedies Sees Revision in Market Evaluation Amidst Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/medico-remedies-upgraded-from-sell-to-hold-by-marketsmojo-on-12-nov-2025-3746591",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/MedicoRemedies_mojoScore_3746591.png",
        "date": "2025-12-04 11:08:06",
        "description": "Medico Remedies, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a nuanced shift in its financial and technical outlook. This adjustment follows a detailed reassessment of the company’s quality, valuation, financial trends, and technical indicators, offering investors a refreshed perspective on its market position."
      },
      {
        "title": "Medico Remedies Forms Golden Cross, Signalling Potential Bullish Breakout",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/medico-remedies-forms-golden-cross-signalling-potential-bullish-breakout-3739076",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/MedicoRemedies_goldencross_3739076.png",
        "date": "2025-12-01 18:00:23",
        "description": "Medico Remedies, a player in the Pharmaceuticals & Biotechnology sector, has recently formed a Golden Cross, a significant technical indicator where the 50-day moving average crosses above the 200-day moving average. This development often signals a potential shift towards a bullish trend and long-term momentum in the stock’s price movement."
      },
      {
        "title": "Is Medico Remedies overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-medico-remedies-overvalued-or-undervalued-3734669",
        "imagepath": "",
        "date": "2025-11-28 08:23:07",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Current Valuation Metrics and Market Performance</strong></p>\n<p>As of 27 Nov 2025, Medico Remedies trades at a price of ₹51.00, slightly up from the previous close of ₹49.86. The stock has experienced a 52-week price range between ₹35.00 and ₹79.78, indicating significant volatility over the past year. Despite a modest weekly return of 0.1%, the stock has outperformed the Sensex over the past month with a 4.27% gain compared to the benchmark’s 1.11%. However, year-to-date returns remain negative at -6.3%, contrasting with the Sensex’s positive 9.7%.</p>\n<p>Longer-term performance shows a mixed picture. While the stock has delivered an impressive 1258.19% return over five years, it has underperformed the Sensex over three years, with a negative 10.16% return versus the Sensex’s 37.61%. This ..."
      },
      {
        "title": "How has been the historical performance of Medico Remedies?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-medico-remedies-3699641",
        "imagepath": "",
        "date": "2025-11-13 23:44:51",
        "description": "Answer:\nThe historical performance of Medico Remedies shows a consistent growth trend in net sales and profits over the years.\n\nBreakdown:\nMedico Remedies has demonstrated a steady increase in net sales, rising from 97.69 Cr in Mar'19 to 150.94 Cr in Mar'25. The total operating income has followed a similar trajectory, reaching 150.94 Cr in Mar'25, up from 144.92 Cr in Mar'24 and 140.44 Cr in Mar'23. The company's operating profit (PBDIT) has also improved significantly, climbing to 17.69 Cr in Mar'25 from 15.04 Cr in Mar'24 and 13.57 Cr in Mar'23. Profit before tax has increased to 13.50 Cr in Mar'25, compared to 11.33 Cr in Mar'24 and 10.10 Cr in Mar'23, while profit after tax reached 10.09 Cr in Mar'25, up from 8.29 Cr in Mar'24. The company's total assets have expanded to 119.55 Cr in Mar'25 from 96.20 Cr in Mar'24, and total liabilities have also increased to 119.55 Cr in Mar'25 from 96.20 Cr in Mar'24..."
      },
      {
        "title": "Medico Remedies Shows Strong Financial Growth Amidst Stakeholder Confidence Concerns",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/medico-remedies-upgraded-to-hold-amid-mildly-bullish-outlook-3696708",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/MedicoRemedies_mojoScore_3696708.png",
        "date": "2025-11-13 08:25:08",
        "description": "Medico Remedies, a microcap in the Pharmaceuticals & Biotechnology sector, has recently adjusted its evaluation, indicating a shift in market sentiment. The company reported strong financial metrics, including a low Debt to EBITDA ratio and significant growth in operating profit and net sales, despite facing some challenges with promoter confidence."
      },
      {
        "title": "How has been the historical performance of Medico Remedies?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-medico-remedies-3695640",
        "imagepath": "",
        "date": "2025-11-13 00:33:37",
        "description": "Answer:\nThe historical performance of Medico Remedies shows a consistent growth trend in net sales and profitability over the years.\n\nBreakdown:\nMedico Remedies has demonstrated a steady increase in net sales, rising from 97.69 Cr in Mar'19 to 150.94 Cr in Mar'25. This growth is accompanied by a rise in total operating income, which reached 150.94 Cr in Mar'25, up from 144.92 Cr in Mar'24. The company's operating profit (PBDIT) has also improved significantly, climbing to 17.69 Cr in Mar'25 from 4.66 Cr in Mar'19, indicating enhanced operational efficiency. Profit before tax has followed a similar upward trajectory, reaching 13.50 Cr in Mar'25 compared to just 2.18 Cr in Mar'19. Consequently, profit after tax has increased to 10.09 Cr in Mar'25 from 1.57 Cr in Mar'19, reflecting a growing profitability margin, which stands at 6.68% in Mar'25. On the balance sheet, total assets have expanded to 119.55 Cr in ..."
      },
      {
        "title": "Why is Medico Remedies falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-medico-remedies-fallingrising-3687348",
        "imagepath": "",
        "date": "2025-11-10 23:51:16",
        "description": "As of 10-Nov, Medico Remedies Ltd is experiencing a price increase, currently at Rs 51.50, reflecting a rise of Rs 1.55 or 3.1%. The stock has shown a positive trend today, outperforming its sector by 2.05% and reversing a two-day decline. It reached an intraday high of Rs 52.44, marking a 4.98% increase. Over the past week, the stock has gained 3.10%, while its performance over the last month is also positive at 2.81%. Despite a year-to-date decline of 5.38%, the company has demonstrated strong fundamentals, including a low Debt to EBITDA ratio of 0.94 times and significant growth in operating profit at an annual rate of 42.16%. However, the stock has underperformed over the past year with a return of -11.68%, despite a 20.7% increase in profits, indicating a potentially expensive valuation.\n\nBroader market context shows that while Medico Remedies has outperformed the sector recently, it has lagged behind ..."
      }
    ],
    "total": 150,
    "sid": "1002925",
    "stock_news_url": "https://www.marketsmojo.com/news/medico-remedies-1002925"
  },
  "announcements": [
    {
      "caption": "Board Meeting Outcome for Outcome",
      "datetime": "14-Nov-2025",
      "details": "Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that the Board of Directors of our Company at their meeting held today i.e. 14th November 2025 has inter alia considered and approved the following: 1. Unaudited Standalone Financial Results for the quarter and half year ended 30th September 2025 alongwith Auditors Limited Review Report thereon; (enclosed) We wish to inform you that the Board Meeting commenced today at 5:00 P.M. and concluded at 06:55 P.M. Kindly take the same on record",
      "source": "BSE"
    },
    {
      "caption": "Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015- Issuance Of GMP Compliance Certificate By The State Service Of Ukraine On Medicines And Drugs Control",
      "datetime": "14-Nov-2025",
      "details": "Please find attached Disclosure under Regulation 30 of SEBI (LODR) Regulations 2015",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order",
      "datetime": "07-Nov-2025",
      "details": "The Company has secured government supply order from the Country of Dominican Republic",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Medico Remedies Ltd has announced <strong>2:10</strong> stock split, ex-date: 16 Mar 23",
          "dt": "2023-03-16",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Medico Remedies Ltd has announced <strong>3:1</strong> bonus issue, ex-date: 16 Nov 21",
          "dt": "2021-11-16",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}
stock newsNews and Views

How has been the historical performance of Medico Remedies?

2025-12-04 22:51:46

Revenue Growth and Operating Performance

Over the past seven years, Medico Remedies has seen its net sales rise from ₹97.69 crores in March 2019 to ₹150.94 crores in March 2025, reflecting a robust compound growth trend. The company’s total operating income mirrors this progression, with no other operating income reported, indicating a primary reliance on core business activities. Raw material costs have naturally increased in line with sales, reaching ₹111.39 crores in the latest fiscal year, while employee costs have also risen steadily, signalling investment in human capital to support expansion.

Operating profit before depreciation and interest (PBDIT) excluding other income has improved significantly, from ₹2.76 crores in 2019 to ₹15.00 crores in 2025. When factor...

Read More

Is Medico Remedies overvalued or undervalued?

2025-11-28 08:23:07

Current Valuation Metrics and Market Performance

As of 27 Nov 2025, Medico Remedies trades at a price of ₹51.00, slightly up from the previous close of ₹49.86. The stock has experienced a 52-week price range between ₹35.00 and ₹79.78, indicating significant volatility over the past year. Despite a modest weekly return of 0.1%, the stock has outperformed the Sensex over the past month with a 4.27% gain compared to the benchmark’s 1.11%. However, year-to-date returns remain negative at -6.3%, contrasting with the Sensex’s positive 9.7%.

Longer-term performance shows a mixed picture. While the stock has delivered an impressive 1258.19% return over five years, it has underperformed the Sensex over three years, with a negative 10.16% return versus the Sensex’s 37.61%. This ...

Read More
stock-recommendationAnnouncement

Board Meeting Outcome for Outcome

14-Nov-2025 | Source : BSE

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that the Board of Directors of our Company at their meeting held today i.e. 14th November 2025 has inter alia considered and approved the following: 1. Unaudited Standalone Financial Results for the quarter and half year ended 30th September 2025 alongwith Auditors Limited Review Report thereon; (enclosed) We wish to inform you that the Board Meeting commenced today at 5:00 P.M. and concluded at 06:55 P.M. Kindly take the same on record

Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015- Issuance Of GMP Compliance Certificate By The State Service Of Ukraine On Medicines And Drugs Control

14-Nov-2025 | Source : BSE

Please find attached Disclosure under Regulation 30 of SEBI (LODR) Regulations 2015

Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order

07-Nov-2025 | Source : BSE

The Company has secured government supply order from the Country of Dominican Republic

stock-recommendationCorporate Actions
Corporate Actions
info
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

Medico Remedies Ltd has announced 2:10 stock split, ex-date: 16 Mar 23

stock-summary
BONUS

Medico Remedies Ltd has announced 3:1 bonus issue, ex-date: 16 Nov 21

stock-summary
RIGHTS

No Rights history available